Arcus Biosciences Inc (NYSE: RCUS) on Tuesday, plunged -4.25% from the previous trading day, before settling in for the closing price of $15.30. Within the past 52 weeks, RCUS’s price has moved between $12.95 and $25.47.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 164.80% annually for the last half of the decade. The company achieved an average annual earnings per share of 19.53%. With a float of $48.24 million, this company’s outstanding shares have now reached $75.50 million.
In an organization with 577 employees, it is important to assess its efficiency.
Arcus Biosciences Inc (RCUS) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Arcus Biosciences Inc is 46.96%, while institutional ownership is 54.15%. The most recent insider transaction that took place on Mar 27 ’24, was worth 202,720. In this transaction Chief Operating Officer of this company sold 11,551 shares at a rate of $17.55, taking the stock ownership to the 215,253 shares. Before that another transaction happened on Mar 18 ’24, when Company’s Chief Operating Officer sold 13,449 for $17.92, making the entire transaction worth $240,941. This insider now owns 226,804 shares in total.
Arcus Biosciences Inc (RCUS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 19.53% per share during the next fiscal year.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
Arcus Biosciences Inc (RCUS) is currently performing well based on its current performance indicators. A quick ratio of 5.22 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.10, a number that is poised to hit -1.12 in the next quarter and is forecasted to reach -4.66 in one year’s time.
Technical Analysis of Arcus Biosciences Inc (RCUS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.92 million. That was better than the volume of 0.79 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 21.52%. Additionally, its Average True Range was 0.82.
During the past 100 days, Arcus Biosciences Inc’s (RCUS) raw stochastic average was set at 8.86%, which indicates a significant decrease from 13.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.79% in the past 14 days, which was lower than the 59.55% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.94, while its 200-day Moving Average is $16.61. However, in the short run, Arcus Biosciences Inc’s stock first resistance to watch stands at $15.24. Second resistance stands at $15.84. The third major resistance level sits at $16.33. If the price goes on to break the first support level at $14.15, it is likely to go to the next support level at $13.66. Assuming the price breaks the second support level, the third support level stands at $13.06.
Arcus Biosciences Inc (NYSE: RCUS) Key Stats
Market capitalization of the company is 1.33 billion based on 90,953K outstanding shares. Right now, sales total 117,000 K and income totals -307,000 K. The company made 145,000 K in profit during its latest quarter, and -4,000 K in sales during its previous quarter.
